Meconium aspiration syndrome treatment - new approaches using old drugs.
Presently, modern medicine does not offer any disease-modifying treatment for meconium aspiration syndrome (MAS). Several medications with already established safety profiles when employed for similar or other conditions could be useful for MAS treatment. N-Acetylcysteine and DNAse have the capability to reduce viscosity and thickness of meconium by breaking disulfide bonds and slicing DNA, respectively. N-Acetylcysteine, antiprotease drugs, or low pH buffer solutions may have the capability to neutralize meconium's digestive enzymes responsible for lung damage in patients with MAS. All these compounds have great potential to reduce meconium's pathogenic properties which in turn could alleviate MAS severity.
Ivanov
Vadim A
VA
Department of Pediatrics, American Clinic, 31, Grokholsky Pereulok, 129090 Moscow, Russia. vadim2@earthlink.net
D000111:Acetylcysteine / Q000627:therapeutic use*; D003851:Deoxyribonucleases / Q000627:therapeutic use*; D006801:Humans; D007231:Infant, Newborn; D008471:Meconium Aspiration Syndrome / Q000188:drug therapy*; D011480:Protease Inhibitors / Q000627:therapeutic use*
D011480:Protease Inhibitors; D003851:Deoxyribonucleases; D000111:Acetylcysteine